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Abstract The pcp2/L7 gene is characterized by its very cell
type-specific expression restricted to cerebellar Purkinje cells
and retinal bipolar neurons. Although remarkable progress as
to the biochemical properties of the encoded protein has been
made, knowledge on its physiological functions remains sparse.
While characterizing a pcp2-driven transgenic strain, we ob-
served the presence of a longer, so far unknown, pcp2 transcript.
Different from another recently discovered splice variant,
ret-pcp2,expressionofthisnoveltranscriptisobservedinbipolar
as well as cerebellar Purkinje cells of mid-postnatal mice. The
protein encoded by our novel variant appears to be less efficient
in binding to Gα subunits compared to the original L7/pcp2
protein and it is also less inhibitory with respect to GTPʳ
binding. Its expression in the eye appears to be independent
from eye opening in postnatal mice.
Keywords pcp2 .L7 .Splicevariant .Cerebellum
Introduction
A remarkable feature of the pcp2/L7 gene is its cell type-
specific expression. Since its discovery in 1988 [20, 21], its
protein and mRNA products have been repeatedly localized
exclusively to cerebellar Purkinje cells (PC) and retinal bipo-
lar cells in various species, including mouse and human
[4, 5, 15, 16, 22, 27, 28, 35].
High conservation of protein and DNA sequence, restricted
expression, and the relatively late appearance of the gene
products after neurogenesis [20, 21, 26, 32, 35]s u g g e s t e d
important roles for neuronal maturation. Besides a partial re-
semblance to platelet-derived growth factor [21], initial se-
quence comparison failed to provide functional insight.
Surprisingly, two different targeted null mutant mouse strains
lacked functional or morphological alterations [17, 27]. More
detailed studies however found, that mice null mutant for pcp2
show enhanced motor learning abilities [11]. Studies into the
cell biology of pcp2 revealed an interesting dissociation of
mRNA and protein localization in PC, with the former accu-
mulating in dendrites and the latter being more equally distrib-
utedwithinallcellular compartments [5,28,34,35]. Moreover,
the potential for activity-dependent regulation of pcp2 was
demonstrated [29]. Insight into function was boosted with the
discovery of interaction of pcp2 protein with Gα subunits
[12–14, 18, 19, 22, 31], and the recognition of other Gα-
interacting proteins sharing a structural feature, the GoLOCO
motif, with pcp2 [23]. While characterizing a pcp2-driven
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DOI 10.1007/s12311-013-0529-0transgenic strain [2, 3], we realized the presence of a longer
pcp2 transcript. Subsequently, we determined its structure,
expression pattern, activity-dependent regulation, and subcel-
lular localization as well as key biochemical properties of the
encoded protein. The alternative transcript characterized here is
different from another recently published product [33, 35].
Material and methods
C57Bl/6 mice were used for all experiments. To determine the
influence of light on pcp2 expression, adult mice or mothers
with their litters were kept in darkness, and then sacrificed in
the dark. Controls were housed under standard light conditions
(12 h light/12 h dark). All animal holding and experiments
were done in accordance with the national animal welfare
regulations and institutional rules.
RNA isolation was performedasdescribed elsewhere[8]. For
reverse transcription, 1 ʼg of total RNA and 0.5 ʼgo l i g o - d T
primer (GIBCO BRL) were mixed in 12 ʼl of Tris-EDTA (TE)
buffer pH 7.4 and then incubated for 5 min at 90 °C, 10 min at
37 °C and 15 min at room temperature. Each sample was then
incubated at 37 °C for 1 h with 4 ʼl 5× first-strand buffer
(GIBCO BRL), 2 ʼlD T T( 0 . 1M ) ,0 . 5ʼlo f0 . 2 5m Md N T P
mix, 0.5 ʼl RNAse inhibitor (40 U/ʼl, Boehringer), and 0.8 ʼl
reverse transcriptase (200 U/ʼl, SuperScript, GIBCO BRL).
Afterwards, 10 ʼl of TE buffer were added to obtain a total
volume of 30 ʼl.
PCR (36 cycles) was carried out on 1 ʼlo fc D N Ai na
reaction mixture containing 1× PCR buffer, 1.5 mM MgCl2,
0.4ʼM ofeachprimer,and0.625 U Taq polymerase(GIBCO
BRL) according to the scheme: 5′95 °C [30″95 °C, 30″72 °C,
1′72 °C] 5′72 °C.
To control for sample loading, reverse transcription poly-
merase chain reaction (RT-PCR) for GAPDH (21 cycles) was
carriedoutforallsamples.Thewholereactionmixture (25ʼl)
was loaded on 2 % agarose gels containing ethidium bromide.
Both splice variants were detected with primers: L7sense 5′-
AAGGCTTCTTCAACCTGCTGA-3′ and L7anti 5′-GCTG
TTCCTGCGGAAGCTGAG-3′. The new splice variant was
specifically detected with primers: L7 sense (as above) and
L73Aanti 5′-TCCCAGTACTCAAGAAACAGG-3′ (Fig. 1b).
GAPDH expression was detected with primers: sense 5′-AC
CACAGTCCATGCCATCAC-3′ and antisense 5′-TCCA
CCACCCTGTTGCTGTA-3′.
To verify the PCR products, bands of interest were extracted
from the gel, subcloned into the pCRII plasmid (TA Cloning
Kit, Invitrogen) and sequenced on an ABI PRISM 377 DNA
Sequencer (Perkin-Elmer). Sequence comparisons were
performed using BLAST (NCBI, Bethesda, MD, USA).
Molecular modeling was performed using the SYBYL soft-
ware, version 7.2 (Tripos Inc.). The model was generated, in
part, by homology modeling with filamentous hemagglutinin
secretion domain (Protein Data Bank, ID code 1rwr) as a
template. The model was energy-minimized using a conjugate
gradient method and subjected to repeating cycles of molecular
dynamics using Kollman force fields and united atoms [30].
In situ hybridization for detection of the novel transcript
was carried out at 38 °C according to a protocol described
elsewhere [24]. The oligonucleotide DNA probe was comple-
mentary to base pairs 2,461–2,507 of the pcp2 genomic se-
quence (Fig. 1a; accession number S40022) [25]. The hybrid-
ization specificity was checked by competing with 100× ex-
cess of the cold probe.
As described later (see “Results” section), the novel longer
transcript encodes a shorter protein variant than the known
shorter transcript. We refer to the native proteins as long pcp2
and short pcp2 proteins, respectively.
For the generation of recombinant glutathione S-transferase
(GST)–pcp2 fusion proteins, cDNAs corresponding to short
andlonger transcript were cloned intothe EcoRI and XhoI sites
of the pGEX-4T-1 vector (GE Healthcare) in frame with the
glutathione-S-transferase/thrombin cleavage site. A single di-
rect primer (L7Eco.d: AGG GCG AAT TCATGG AGG AGC
AGC GCT GTT C), containing an EcoRI site, was used to
amplify both forms of pcp2 from mouse cerebellar cDNA. As
reverse primers, both containing an XhoI restriction site,
L7lgXho.r ( TAG GAT CTC GAG AAC TCT CAA GGA
GCTTGTG)providedspecificityfortheshorttranscript,while
L7shXho.r (AAC AGG CTC GAG GAT TAT TTT GAG TTC
AAA GC) amplified the long transcript only.
The resulting plasmids (GLL7 for the long form and GSL7
for the short form) were transformed into the JM109
Escherichia coli to yield recombinant proteins (we refer to
the GST-short pcp2 protein as SL7 and to the GST-long pcp2
protein as L7) as was the empty pGEX vector for the produc-
tion of GST alone as a control. Proteins were obtained after
1 mM IPTG induction and purified by sepharose–glutathione
affinity chromatography. Purity and integrity of the recombi-
nant fusion proteins were verified by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; not shown).
Recombinant baculovirus expressed purified Gαoa n dG αi1
[10] were kindly provided by Steve Graber (Morgantown West,
VA, USA) and were preincubated at 1:1 M ratio (2.5 pmol) with
purified noncleaved GST fusion proteins for AGS3 (cDNA
provided by Steve Lanier, New Orleans, LA, USA), long pcp2,
short pcp2, and GSTalone in buffer A (20 mM HEPES, pH 8.0,
130 mM NaCl, 3 mM MgCl2, 1 mM DTT, 1 mM EDTA, 10 ʼg/
ʼl,bovineserumalbumin,and0.1%TritonX-100) for20minat
25 °C in the presence of 1 ʼM GDP. At t=0,GTPʳS
35 (1 ʼM;
specific activity, 1×10
5 cpm/pmol, New England Nuclear) was
addedfor 60min.Reactions wereterminated bydilutionintoice-
cold phosphate-buffered saline (PBS) and rapidly filtered
through 25 mm round nitrocellulose membranes (Millipore,
Billerica, MA, USA; 0.45 ʼM HA), washed twice with 20 ml
of cold PBS. Filters were placed in scintillation fluid and counted
208 Cerebellum (2014) 13:207–214in a Packard Tri-Carb A2200 liquid scintillation counter. Blank
filters (no protein) were used to determine background and non-
specific binding was determined with parallel filters incubated
with excess (0.1 mM) cold GTPʳS( S i g m a ) .
In vitro translated Gαsubunits were [S
35]-methionine labeled
and prepared as previously described using the TNT coupled
in vitro translation system (Promega) [9]. Similar amounts of
translate (5–10 ʼl) were incubated with 0.3 ʼg of GST, AGS3,
long pcp2, or short pcp2 for 2 h at room temperature in buffer
A +0.1 % Triton X-100, 150 mM NaCl, and 20 ʼM GDP
(binding buffer). Glutathione agarose beads were added for
30minatroom temperature,centrifuged,andwashedthreetimes
with 1 ml ice-cold binding buffer. Samples were eluted in 2×
SDS-PAGE sample buffer by heating at 100 °C for 5 min and
analyzed by SDS-PAGE and autoradiography.
Results
RT-PCR on eye and cerebellar RNA using primers placed in
exon 2 (L7sense) and 4 (L7anti) (Fig.1b), consistently detected a
novel 350 bp product together with the 300 bp band expected
2333  TGTTTGTTTTAG                                                           GTATACACTAAC  2416
exon 3B
TER
TATTTAGCTTTGAACTCAAAA   TCCTCCTGCCTGTTTCTTGAGTACTGGGATTACAG TAA TATTTAGCTTTGAACTCAAAA   TCCTCCTGCCTGTTTCTTGAGTACTGGGATTACAG TAA
b
c
d
short pcp2
long pcp2
MEEQRCSLQAGPGQNPESQGGPAPEMDNLMDMLVNTQGRRMDDQRVTVDSLPGFQPIGPKYLALNSK
ATG
4kb 300
70 11 5 125 58 182
150 754 134 2kb
I II II III III IV IV
a
1 3 2
short pcp2
long pcp2
MEEQRCSLQAGPGQNPESQGGPAPEMDNLMDMLVNTQGRRMDDQRVTVDSLPGFQPIGPKDGMQKRPGTLSPQPLLTPQDPAALSFRRNSSPQPQTQAP
short pcp2 long pcp2
Fig.1 Structure and sequence ofthenovel pcp2 transcriptand protein. a
Structureofthetranscriptsforlongandshortpcp2(longandshortreferto
the protein and not to the mRNA). Gray and black boxes indicate
previously known exons and the novel exon 3B, respectively. Lengths
of exons and introns are indicated in base pairs. Arrows indicate primers
used for RT-PCR. 1 L7sense, 2 L7anti, 3 L73Aanti. b Nucleotide
sequence of exon 3B (bold italic) with intronic junctions. TER indicates
the in-frame translation stop codon, and the gray-shaded box is the
complement of the in situ hybridization probe. c Sequence of short and
longpcp2 proteins. The gray-shaded box represents the GoLOCO motif.
Sequences unique to either protein are framed, and predicted C-terminal
phosphorylation sites are underlined with the phosphorylated serine
being indicated by an upward arrow. d Computer-generated models of
longand short pcp2. C-terminaldomains thatdistinguish the twovariants
are indicated in orange. Red cylinders represent α-helical structures of
the GoLOCO domain
Cerebellum (2014) 13:207–214 209from the known pcp2 gene structure (Fig. 2). Sequencing and
analysis of the RT-PCR product revealed a novel stretch of 58 bp
between 2,455 and 2,513 bp within intron 3 (Fig. 1a). This
analysis also revealed splice donor and acceptor sites flanking
this exon. The novel exon, dubbed 3B, can be included or
excluded resulting in two different pcp2 transcripts (Fig. 1b). In
the following, we will refer to the originally published exon 3 as
exon 3A. Interestingly, when included, exon 3B introduces an in
frame stop codon. Thus, exon 4 does not contribute to the coding
of this alternative product. As the translated product is 32 amino
acids shorter than the originally published protein (here referred
to as long pcp2 protein), we call it short pcp2 protein. The
GoLOCO motif of long pcp2 is found between amino acids 27
and 45, and is entirely encoded by exon 3A. It is, therefore, not
altered in short pcp2. The C-terminal, exon 4-encoded part of
pcp2 contains a cluster of predicted phosphorylation sites (scores
higher than 0.95; NetPhos 2.0, CBS Technical University of
Denmark) [6]. These are a putative PKC site at serine 85
(PAALSFRNN), a CaM kinase II/PKA site around serine 90
(FRRNSSPQP), and a Cam kinase II/PKA/PKG site around
serine 91 (Fig. 1c). Two of them are conserved between mouse,
rat, and human [35]. With the exception of another predicted site
at serine 18 (QNPSESQGGP), none of the putative phosphory-
lation sites of long pcp2 is present in the short pcp2.
Computer analysis of long and short pcp2 protein variants
did not reveal many characteristic structural motives. Except
for α-helical domains corresponding to the GoLOCO motif,
the proteins are essentially characterized by an extended
structure (Fig. 1d).
To study expression of the novel transcript, we designed a
primer placedinthenovelexon3B(L73Aanti; Fig.1b).RT-PCR
using primers L7sense and L73Aanti confirmed the presence of
the novel transcript in eye and cerebellum of adult mice (Fig. 2).
During development, expression of the novel form is first detect-
ed between P12 and P14 in eye and cerebellum. The presence of
the long form was observed already at P7 (data not shown).
To localize the novel transcript at the cellular level, in situ
hybridizationwas performedoncerebellarandretinalsections
P1 P7 P12 P14 P19 6M
GAPDH
Short pcp2
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
cerebellum
eye
eye
eye
eye
eye
eye
eye
eye
eye
eye
eye
Fig. 2 Developmental
expression of the novel pcp2
transcript. Transcripts encoding
short pcp2 protein were detected
by transcript-specific RT-PCR at
theindicatedpostnataltimepoints
(upper panel)
f
PE
RC &
ONL
OPL
INL
IPL
GCL
e d
g
p
m
a
c
b
Fig. 3 Localization of transcripts
coding for the novel short pcp2
protein by in situ hybridization
in adult C57BL/6 mice. a Dark
field imaging of the cerebellar.
g Granular cell layer, p Purkinje
cell layer, m molecular layer.
Bar 100 ʼm. b Control section.
Bar 100 ʼm. c Bright field
picture of Purkinje cells showing
silver grains over cell bodies of
Purkinje cells (arrow heads). Bar
100 ʼm. d Phase contrast image
of mouse retinal layers. PE
pigment epithelium, R&C rod
and cone photoreceptors, ONL
outer nuclear layer, OPL outer
plexiform layer, INL inner
nuclearlayer,IPL innerplexiform
layer, GCL ganglion cell layer.
Bar 100 ʼm. e Dark field image
of a hybridized retina section.
Bar 100 ʼm. f Control section.
Bar 100 ʼm
210 Cerebellum (2014) 13:207–214using an oligonucleotide probe corresponding to 46 bp of
exon 3B. Microscopic analysis revealed specific signals with-
in the cerebellar cortex at the level of the PC layer (Fig. 3a, b).
Higher magnification microscopy revealed the presence of
silver grains over the cell bodies of PC (Fig. 3c). In sections
of the retina, labeling was detected in the outer part of inner
nuclear layer, where bipolar neurons are localized (Fig. 3d, e).
Specific signal was also found at the outer plexiform layer.
Because expression of transcripts encoding the novel short
pcp2 protein was first detected around the time of eye opening
in mice (P12-14) [25], we wondered whether it would be mod-
ulated by maintenance of mice in the dark (Fig. 4). Pcp2 expres-
sion was analyzed in adult animals housed in the dark for 60 h or
6days,respectively,andcomparedtoanimalskeptunderstandard
light–dark conditions (Fig. 4a). After the indicated time, animals
were sacrificed in the dark, and tissue samples were immediately
dissected for analysis. RT-PCR using the exon 2–exon 4 primer
pair detected the presence of both transcripts in the eye and the
cerebellum. It failed, however, to reveal any differences between
groups. To investigate a possible induction of expression by light
at the time of eye opening, P1 litters were maintained in the dark
together with their mothers (Fig 4b). Pups were sacrificed in the
dark at P15 and P19, tissues dissected and RT-PCR performed as
above. Controls were pups kept under standard light–dark condi-
tions. Again, both splice variants were detected in both tissues at
levels apparently not influenced by dark rearing.
To investigate whether short pcp2 protein functions as a
GDI for Gα subunits, we first examined whether short pcp2
interacts withGαsubunits.Figure 5ashows invitrotranslated
and [S
35]-methionine labeled Gαo, Gαi 1 ,2 ,a n d3u s e di n
GST pull-down experiments with GST (negative control),
AGS (positive control), long pcp2 (L7), and short pcp2
(SL7). The GST proteins are shown in the Coomassie-stained
gel below and the amount of labeled Gα subunit precipitating
under eachconditionisshown intheautoradiogram.Therelative
interaction of SL7 and L7 with Gαi1, Gαi-2, Gαi-3, and Gαoi s
s u m m a r i z e di nt h eb a rg r a p h s( F i g .5b) relative to the AGS3
binding for this experiment. The experiment was repeated twice
with similar results. It appears that for all four tested Gα sub-
units, the preferential binding was AGS>>long pcp2>short
pcp2. Albeit, binding of SL7 was weak when compared to
AGS3 it was higher than binding of GST alone. Importantly,
binding of SL7 was clearly less than that of LL7. As expected
from other reports [18], binding to Gαo was weak for all three
G S Tf u s i o np r o t e i n si nc o m p a r i s o nw i t ht h eG αi family. There
did not appear to be any preference for short pcp2 in comparison
with long pcp2 for interacting with Gαo or any of the Gαi
subunits.
We next examined the GDI potency of short pcp2 protein
in comparison with long pcp2 and AGS3 (Fig. 5c).
Baculovirus-purified Gαoa n dG αi1 were used for these
experiments and GTPʳS
[35] binding to each Gα subunit was
compared in the presence and absence of GST (negative
control and binding set to 100 %), GST-pcp2 long (L7),
GST-pcp2 short (SL7), and GST-AGS3 under conditions very
similar to those previously used to characterize differences
between pcp2 and AGS proteins (e.g., [7]). The degree of
GTPʳS
[35] inhibition in these conditions mirrored the binding
results shown in Fig. 5a, b. There was a small but consistent
inhibition of GTPʳS
[35] binding to purified Gαo( F i g .5c)a n d
there was no significant difference in inhibition for AGS3,
short or long pcp2. However, the inhibition of GTPʳS
[35]
binding to Gαi1 revealed relative potencies indicated already
by the binding experiments; AGS3>long pcp2>short pcp2.
There wasnosignificant difference ininhibitionofGTPʳS
[35]
binding to Gαi1 for short or long pcp2, but short pcp2 protein
was significantly different from control and AGS3. Taken
together, the GST pulldowns and GTPʳS
[35] binding results
are consistent with short pcp2 binding less avidly toGαi1and
therefore being a slightly less effective GDI than long pcp2.
Discussion
Our study describes alternative splicing of the pcp2/L7 gene.
The protein product encoded by the novel long transcript
(short pcp2 protein) lacks most of the carboxy-terminal half of
the originally described protein (long pcp2 protein), but still
contains the N-terminal GPR motif. It is different from the
60
hours
6
days control
GAPDH
cerebellum
cerebellum
cerebellum
eye
eye
eye
- 300bp
- 350bp
control
- 300bp
- 350bp
P1 9
GAPDH
cerebellum
cerebellum
cerebellum
eye
eye
eye
a
b
P1 5 P1 9
Fig.4 Influenceofdarkbreedingonexpressionofpcp2.a AdultC57Bl/6
mice were kept in darkness for 60 h or 6 days after which tissues were
processed for RT-PCR common for both transcripts. b P1 pups were kept
in darkness with their mothers until tissue dissection at P15 and P19.
Controls were kept under standard light conditions. The length of the
amplimers is given in base pairs
Cerebellum (2014) 13:207–214 211product of a recently described alternative splicing of 5′ exons
[35]. Several additional features distinguish long from short
pcp2 protein. First, there seem to be differences as to the
developmental time course of expression. The novel transcripts
appear to occur later although more detailed expression analysis
is needed to exclude misleading effects of its low expression
level. Our data on short pcp2 together with previous work [35]
suggestthat,atleastinthecerebellum,bothformsco-existinthe
same cell. Its expression in retina and cerebellum distinguishes
our transcript from a previously described splice variant, coined
ret-pcp2, which is exclusively expressed in retinal bipolar cells
and accelerates light responses [33]. Thus, generation of our
short form could be readily explained by assuming that the
alternativeformdependsonmaturationofthesplicingapparatus
and is cell autonomous, or is induced by extrinsic systemic
factors, e.g., hormones. It is of interest in this context, that
expression of the transcripts encoding long pcp2 protein is
transcriptionally activated by thyroid hormone during the sec-
ond and third week of cerebellar development in the rat [1].
Earlier transcriptional activation by thyroid hormone appears to
be repressed by a DNA-binding protein. Similar mechanisms,
e.g., blockade of cis-acting splicing enhancers, could explain
the developmental pattern of alternative splicing observed here.
In contrast, use-dependent activity in the retina as initiated by
eye opening is not a major factor regulating this process.
Second, biochemical properties of short and long form differ.
When recombinant Gαsubunits are used, both forms act as GDI,
with long pcp2 protein being more potent. The meaning of
increased amounts of a weaker GDI during development is
unclear at present. Short pcp2 might replace long forms at some,
Fig. 5 Interaction with G protein α-subunits. a Interaction of Gα Sub-
units with short and long pcp2 protein. The indicated in vitro translated
and S
35-methionine labeled Gα subunits were incubated with recombi-
nantGSTfusionsofAGS3,andshort(SL7)andlongpcp2(L7),andGST
alone, and then precipitates were analyzed by SDS-PAGE (see “Material
and Methods” for details). Top panel the left lane is 5 % (Gαi2, Gαi3) or
10 % (Gαo, Gαi1) of input into the binding. Precipitated Gα subunits
with each of the GST fusion proteins are shown in the subsequent lanes.
The bottom panel shows Coomassie blue stained gel of the fusion
proteins used in the binding experiments. Exposures are 24–48 h. b
The binding of each Gα subunit to L7 and SL7 is shown relative to the
AGS3 binding. c GTP binding to baculovirus-purified Gαo( top)a n d
Gαi1 (bottom) in absence or presence of recombinant GST fusions of
AGS3, short pcp2 (SL7), and long pcp2 (L7) (see “Material and
Methods” for details). Specific binding of GTPʳSt oG α subunits was
determined in triplicate and set to 100 %. Results are the mean values±
SEM (Gαo, n=8;Gαi1, n=6 independent experiments). In comparison
to Gαo alone, all three fusion proteins had small but significant reduc-
tions in GTPʳS binding (SL7, p=0.017; L7 and AGS3, p<0.001). For
Gαi1, p=0.036 for SL7 and p<0.001 for L7 and AGS3. The differences
between short and long pcp2, and long pcp2 and AGS3 did not reach
statistical significance, but short pcp2 was significantly different from
AGS3 (p=0.003)
212 Cerebellum (2014) 13:207–214but not all, specific intracellular sites. Transfection ex-
periments so far failed to reveal such specific intracellu-
lar targeting (data not shown). This might be due to
m a s k i n gc a u s e db yo v e r e x p r e s s i o no ft h ep r o t e i n .
Alternatively, the upregulation of the short form might
tune the interaction of the long form in homo- or
heteromeric molecular complexes. Our data indicate that
relative expression of short to long variant is stronger in
retina than cerebellum. This might suggest that retinal
bipolar cells, which are known to express an additional
specific pcp2 isoform [33], might be particularly depen-
dent on fine tuning of pcp2 and G-protein function. It is
interesting to speculate on the differing potencies of GDI
activity of long and short pcp2. Both proteins contain a
single GoLOCO motif, so the differences are likely to
result from important other conformational or structural
differences between the isoforms. Further differentiation
in the biochemical properties of the short variant might
depend on the use of the alternative exon 1B, which
would introduce a second GoLOCO motif [35]. We can-
not exclude that functional differences between both
forms are stronger when additional Gα subunits are
tested. In addition, there are intriguing differences in
putative post-translational modifications of short and
long pcp2.
A cluster of phosphorylation sites predicted in the C-
terminusoflongpcp2islostinthe short variant.Thisincludes
a site for phosphorylation by protein kinase G, which is
abundantly expressed in PC, and possibly also in retinal
bipolar cells. Further experimentation has to be awaited to
see whether pcp2 is indeed a substrate for G kinase, and
subsequently,howhyperphosphorylationwouldinterferewith
the developmental function of pcp2.
As indicated by the work on ret-pcp2 [33], pcp2 splice
variants subserve delicate and important biological roles.
These might depend on the proportion of the different
splice forms and their products. Future progress in under-
standing the biological function of pcp2 will require a
careful comprehensive analysis of the expression of all its
different splice variants.
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